C4 Therapeutics appoints Steve Hoerter to its Board, enhancing oncology expertise to advance targeted protein degradation innovations.
Quiver AI Summary
C4 Therapeutics, Inc. has announced the appointment of Steve Hoerter to its Board of Directors, marking a significant step in the company's evolution as it advances its pipeline of targeted protein degraders. Hoerter brings over 30 years of oncology commercialization and leadership experience, having most recently served as the CEO of Deciphera Pharmaceuticals, which was acquired for $2.4 billion. He previously held executive roles at Agios Pharmaceuticals, Clovis Oncology, and major companies like Roche and Eli Lilly. C4 Therapeutics aims to develop innovative treatments for cancer using its TORPEDO platform, and Hoerter's expertise is expected to propel the company forward in its mission to improve patient outcomes with novel therapies.
Potential Positives
- The appointment of Steve Hoerter to the Board of Directors enhances C4T's leadership team with over three decades of oncology commercialization and executive experience.
- Mr. Hoerter's experience from leading Deciphera Pharmaceuticals through a successful acquisition is a strong indicator of his capability to guide C4T's growth and overcome challenges in bringing innovative therapies to market.
- His proven track record in advancing oncology programs aligns well with C4T's focus on novel targeted protein degraders, indicating strategic potential for future commercialization of their pipeline products.
- Hoerter's excitement about joining C4T suggests positive momentum and confidence in the company's mission, which may attract investor interest and support for ongoing development efforts.
Potential Negatives
- The focus on the transformation of the Board of Directors may imply previous inadequacies or lack of diverse expertise within the current board, raising concerns about past governance issues.
- Mr. Hoerter's previous company, Deciphera Pharmaceuticals, was recently acquired, which could suggest a transition phase for C4T amidst uncertainty regarding its own market position and pipeline advancement.
- The press release emphasizes the company's ambition to become fully integrated, which might highlight existing limitations in its current capabilities or operational maturity.
FAQ
What is the significance of Steve Hoerter's appointment at C4 Therapeutics?
Steve Hoerter's appointment enhances the Board's expertise in oncology commercialization and supports C4T's transition to a fully integrated biotech company.
What experience does Steve Hoerter bring to C4 Therapeutics?
Steve Hoerter has over three decades of experience in executive management and commercialization within the oncology sector.
How will C4T benefit from targeted protein degradation?
C4T's targeted protein degradation approach aims to create innovative therapies that can improve patient outcomes by overcoming drug resistance and targeting undruggable diseases.
What are C4 Therapeutics' main research focuses?
C4T is focused on developing small-molecule degraders for challenging cancer targets and advancing its clinical oncology programs.
Where can I find more information about C4 Therapeutics?
For more details, visit C4 Therapeutics' official website at .
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CCCC Hedge Fund Activity
We have seen 69 institutional investors add shares of $CCCC stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ORBIMED ADVISORS LLC added 2,864,842 shares (+189.3%) to their portfolio in Q3 2024
- SOLEUS CAPITAL MANAGEMENT, L.P. added 2,552,000 shares (+63.0%) to their portfolio in Q3 2024
- BALYASNY ASSET MANAGEMENT L.P. removed 1,916,395 shares (-99.0%) from their portfolio in Q3 2024
- TCG CROSSOVER MANAGEMENT, LLC removed 1,276,574 shares (-100.0%) from their portfolio in Q3 2024
- MORGAN STANLEY added 1,188,196 shares (+104.4%) to their portfolio in Q3 2024
- POINT72 ASSET MANAGEMENT, L.P. added 923,268 shares (+331.4%) to their portfolio in Q3 2024
- WASATCH ADVISORS LP added 830,218 shares (+17.1%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience
Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director.
"Our commitment to assembling a group of industry experts who offer diverse perspectives to our Board has resulted in bringing on some of the industry's brightest minds, from leaders in asset discovery, to discovery, clinical development and corporate governance experts. As we continue advancing our portfolio of novel degraders, on behalf of the Board, I am thrilled to welcome Steve Hoerter and his deep product commercialization experience," said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. "Steve's proven expertise in strategically advancing oncology programs into the commercial market will help guide our plans to become a fully integrated biotechnology company bringing innovative small molecule degraders to patients."
Mr. Hoerter has over three decades of executive management, commercial and board experience, most recently serving as the president and chief executive officer of Deciphera Pharmaceuticals, which was acquired by ONO Pharmaceutical for $2.4 billion in June 2024. He transformed Deciphera from a clinical-stage company into a fully integrated global organization with the successful approval and launch of QINLOCK
for the treatment of advanced gastrointestinal stromal tumors in the U.S. and Europe, while advancing the company's pipeline of novel product candidates. Prior to Deciphera, he was chief commercial officer of Agios Pharmaceuticals, where he was responsible for building the company's commercial organization to enable the launches of its first two approved products in the U.S., TIBSOVO
and IDHIFA
, both for the treatment of acute myeloid leukemia. Earlier in his career, he served as chief commercial officer of Clovis Oncology and held general management and commercial roles at Roche, Genentech, Chiron Corporation (acquired by Novartis) and Eli Lilly and Company. Mr. Hoerter is on the Board of Directors of ORIC Pharmaceuticals, a clinical-stage oncology company, and has previously served on the Boards of Constellation Pharmaceuticals (acquired by MorphoSys), Deciphera Pharmaceuticals and Ignyta (acquired by Roche). He earned his B.A. from Bucknell University, his M.B.A. from Tilburg University in the Netherlands and an M.S. in management from the Krannert School of Management at Purdue University.
"I am excited to join the C4T Board as the Company advances its pipeline of novel targeted protein degraders that have the potential to disrupt the treatment landscape and improve outcomes for patients," said Mr. Hoerter. "C4T is a leader in the field of targeted protein degradation, with a rich pipeline of orally bioavailable small-molecule degraders targeting challenging cancer targets with significant unmet needs. I look forward to supporting C4T's continued evolution as it advances new therapies for patients."
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO
platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T's degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit
.
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
A photo accompanying this announcement is available at
.
